Avaliação de um modelo diferenciado de localização e gestão ativa de casos no local de atendimento para eliminar a transmissão do HIV de mãe para filho no Malaui (PAC-Man)
UNCPM 22401 - Avaliação de um modelo diferenciado de detecção e gestão ativa de casos no local de atendimento para a eliminação da transmissão vertical do HIV em Lilongwe e Mangochi, Malawi
Purpose: To conduct a hybrid effectiveness-implementation stepped-wedge trial to:
- Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of infants who receive timely EID testing.
- Estimate the effect of the PAC-Man model, compared to SOC, on the proportion of pregnant and breastfeeding women living with HIV who receive guideline-adherent viral load testing.
- Compare implementation outcomes between the PAC-Man model and SOC.
Participants: The total study sample size is 2,426, including 2,304 mother-infant pair (MIP) survey participants, 48 high-risk pregnant/breastfeeding women living with HIV for in-depth interviews (from high-risk MIPs who participated in a survey); 10 PMTCT policy makers and Ministry of Health (MOH)/ President's Emergency Plan for AIDS Relief (PEPFAR) implementing partner senior managers for key informant interviews; and about 48-64 professional and lay health providers for focus group discussions and implementation actor surveys.
To rigorously evaluate the PAC-Man model, investigators will use a hybrid (type 3) effectiveness-implementation incomplete stepped-wedge trial design. The hybrid incomplete stepped-wedge design is a rigorous quasi-experimental design that allows for incremental "rollout" of the PAC-Man model and serial measurement of both health outcomes (for infants and mothers in Objectives 1 and 2, respectively), as well as implementation outcomes (Objective 3). The incomplete stepped-wedge design is more efficient than a complete design, minimizes costs, and reduces participant burden, without sacrificing statistical precision. Using this design, sequential crossover from control (i.e., the SOC) to intervention (i.e., SOC plus the PAC-Man model) takes place at each 'step' using cluster randomization until all clusters (defined as a group of "sites," or health facilities plus the surrounding communities in its catchment area) receive the intervention. The 12 sites included in our study will be divided into 4 clusters of 3 sites each.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
PAC-Man Model:
PAC-Man represents an integrated differentiated services delivery (DSD) model for mothers and infants that brings the following three evidence-based practices into the community for elimination of mother to child transmission (EMTCT): 1) pediatric active case finding using novel point-of-care (POC) early infant diagnosis (EID) technology; 2) same-day antiretroviral therapy (ART) initiation for infants newly diagnosed with HIV infection; and 3) maternal viral load (mVL) testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach "high risk" MIPs in which the mother living with HIV did not initiate ART, started ART late during pregnancy or breastfeeding, dropped off treatment following ART initiation, was unsuppressed on ART, was identified with HIV infection for the first-time during the post-partum period, and/or did not return with her infant for EID testing. Because these evidence-based practices are already recommended by the Ministry of Health and will be functioning at the site and not the individual level, delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA™ in community settings.
PAC-Man Implementation Approaches:
The overall implementation strategy being evaluated in this study is the creation of mobile care teams to deploy m-PIMA™ and provide EMTCT services in the community. Complementing this overarching strategy will be two sub-strategies used to enhance PAC-Man adoption: 1) task shifting of active case finding, EID and mVL testing, ART initiation, and back-to-care services to community health workers (CHWs), community nurses, and HIV diagnostic assistants; and 2) changing service sites to convenient locations in the community to overcome barriers to EID and mVL delivery. These strategies are intended to work in concert with the above evidence-based practices to integrate PAC-Man into the EMTCT program.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Michael Herce, MD, MPH
- Número de telefone: 9198435996
- E-mail: michael_herce@med.unc.edu
Locais de estudo
-
-
-
Lilongwe, Malauí
- Recrutamento
- Area 18 Health Centre
-
Contato:
- Chimwemwe Kumwenda
- Número de telefone: +265-999-265626
- E-mail: ckumwenda@unclilongwe.org
-
Monkey Bay, Malauí
- Recrutamento
- Monkey Bay Community Hospital
-
Contato:
- Chimwemwe Kumwenda
- Número de telefone: +265-999-265626
- E-mail: ckumwenda@unclilongwe.org
-
-
Central Region
-
Lilongwe, Central Region, Malauí
- Ainda não está recrutando
- Bwaila Hospital
-
Contato:
- Michael Herce, MD, MPH
- Número de telefone: 9198435996
- E-mail: michael_herce@med.unc.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
The criteria for Enumerated MIP Cohort is as follows:
Inclusion Criteria:
- Enrolled in the national EMTCT program at a study site in the 12 months preceding a survey.
Exclusion Criteria:
- None.
The criteria for Enumerated MIP Field Survey is as follows:
Inclusion Criteria:
- Age 16 years or older.
- Enrolled in the national EMTCT program at a study site in the 12 months preceding a survey.
Exclusion Criteria:
- Documented transferred out from a site prior to the field survey.
- Participated previously in the field survey.
- Decline informed consent.
The criteria for In-Depth Interviews is as follows:
Inclusion criteria:
- Age 16 years or older.
- Met high-risk criteria for PAC-Man model.
- Participated in a field survey.
Exclusion criteria:
- Decline informed consent.
The criteria for Focus Group Discussions is as follows:
Inclusion criteria:
- Age 18 years or older.
- MOH or implementing partner professional or lay health worker at a study site (such as nurses, community health workers, health surveillance assistants, and HIV diagnostic assistants)
- Generally familiar with the PAC-Man model and/or EMTCT/ EID service delivery at their site.
Exclusion criteria:
- Decline informed consent.
The criteria for Key Informant Interviews is as follows:
Inclusion criteria:
- Age 18 years or older.
- HIV/ EMTCT policy maker OR MOH/ PEPFAR implementing partner senior manager.
- Generally familiar with HIV and/or EMTCT/ EID service delivery.
Exclusion criteria:
- Decline informed consent.
The criteria for Implementation Actor Questionnaires is as follows:
Inclusion criteria:
- Age 18 years or older.
- Professional or lay health provider at a study site.
- Generally familiar with HIV and/or EMTCT/ EID service delivery at their site.
- Participated in a focus group discussion.
Exclusion criteria:
- Decline informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: PAC-Man Model
PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach "high risk" MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings. |
PAC-Man represents an integrated DSD model for mothers and infants that brings the following three evidence-based practices into the community for EMTCT: 1) pediatric active case finding using novel POC EID technology; 2) same-day ART initiation for infants newly diagnosed with HIV infection; and 3) mVL testing and back-to-care services. PAC-Man uses a mobile approach to offer EMTCT services in the community and reach "high risk" MIPs. Delivering the PAC-Man model will be done under the auspices of routine care, applying an overarching implementation strategy of creating new mobile care teams equipped with new diagnostic technology who deploy the m-PIMA in community settings. |
|
Comparador Ativo: Standard of care (control arm)
Routine care as provided by the Ministry of Health. |
Routine care as provided by Ministry of Health. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of infants who receive EID testing by age 6 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants exposed to HIV who receive EID testing by age 6 months among the enumerated cohort of MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of infants who receive EID testing by age 2 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants exposed to HIV who receive EID testing by age 2 months among the enumerated cohort of all MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants who receive EID testing by age 12 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants exposed to HIV who receive EID testing by age 12 months among the enumerated cohort of all MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk infants who receive EID testing by age 6 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants with high-risk mothers exposed to HIV who receive EID testing by age 6 months among all high-risk MIPs with infants at least 6 weeks old at all study sites. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants who initiate ART
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants newly diagnosed with HIV who initiate ART ≤60 days from EID sample collection among the enumerated cohort of all infants. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Median infant results return time
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Median number of days from infant EID sample collection to results returned to caregivers. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants newly diagnosed with HIV
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants newly diagnosed with HIV among the enumerated cohort of all infants. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Median age at ART initiation among infants
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Median age in months at ART initiation among infants who test positive for HIV. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Median time to ART initiation among infants
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Median number of days to ART initiation among infants who test positive for HIV. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants who initiate ART the same day as diagnosis
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants newly diagnosed with HIV who initiate ART on the same day as EID results received among the enumerated cohort of all infants. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants with HIV retained in care at 3 months post-ART initiation
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants with HIV who are retained in care at 3-months post-ART initiation. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of infants with HIV retained in care at 6 months post-ART initiation
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of infants with HIV who are retained in care at 6-months post-ART initiation. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs reached with viral load testing
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers living with HIV who received MOH-recommended 6-monthly VL testing during pregnancy and breastfeeding among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk MIPs reached with viral load testing
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of high-risk MIPs living with HIV who received MOH-recommended 6-monthly VL testing during pregnancy and breastfeeding among all high-risk MIPs from the enumerated cohort. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs virally suppressed at 6 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers with viral suppression (<1,000 copies of HIV per ml.) at 6 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk MIPs virally suppressed at 6 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of high-risk mothers with viral suppression (<1,000 copies of HIV per ml.) at 6 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs virally suppressed at 12 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers with viral suppression (<1,000 copies of HIV per ml.) at 12 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of high-risk MIPs virally suppressed at 12 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of high-risk mothers with viral suppression (<1,000 copies of HIV per ml.) at 12 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs retained in care at 6 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers who are retained in care (≥1 clinic encounter within the last 180 days) at 6 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs retained in care at 12 months
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers who are retained in care (≥1 clinic encounter within the last 180 days) at 12 months after EMTCT enrollment among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs who resumed ART
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of mothers who had documented treatment interruption (i.e., a treatment gap ≥28 days) who later resumed ART among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Proportion of MIPs who received enhanced adherence counseling
Prazo: Within 12 months of MIP enrollment in the national EMTCT program
|
Proportion of MIPs who had unsuppressed viral load and then completed enhanced adherence counselling among the enumerated cohort of all MIPs. |
Within 12 months of MIP enrollment in the national EMTCT program
|
|
Adoption - proportion of sites that adopt the PAC-Man model
Prazo: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Number of trained sites that deliver the PAC-Man intervention divided by the total number of trained sites. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
|
Adoption - proportion of providers who adopt the PAC-Man model
Prazo: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Number of trained providers who deliver the PAC-Man intervention divided by the total number of trained providers. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
|
Implementation - cost per pediatric case
Prazo: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Incremental cost of PAC-Man implementation per pediatric HIV case identified, compared to standard of care. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
|
Implementation - cost per unsuppressed MIP
Prazo: 6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Incremental cost of PAC-Man implementation per pregnant and breastfeeding woman with unsuppressed viral load identified, compared to standard of care. Study endline sustainability survey is conducted at the end of the trial once all study sites have been randomized to receive the intervention. |
6-12 months after sites switch to intervention; study endline (Approximately 12 months from the time that last study sites are switched to the intervention)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Michael Herce, MD, MPH, University of North Carolina, Chapel Hill
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 24-0561
- 1P01HD112215 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with The University of North Carolina at Chapel Hill (UNC).
Prazo de Compartilhamento de IPD
Beginning 9 and continuing for 36 months following publication
Critérios de acesso de compartilhamento IPD
Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .